Le Lézard
Classified in: Health
Subjects: RCL, MAT

F&S Medical Supply, DBA Pink Toyz Issues Voluntary Nationwide Recall of Pink Pussycat Capsules Due to the Presence of Undeclared Sildenafil


Recalling Pink Pussycat Sensual Enhancement pill sold by Pink Toyz

CHATSWORTH, Calif., April 1, 2022 /PRNewswire-PRWeb/ -- F&S Medical Supply, dba Pink Toyz is voluntarily recalling one lot of Pink Pussycat 3000 mg capsules to the consumer level. FDA analysis has found the product Pink Pussycat to be tainted with sildenafil, an ingredient known as a phosphodiesterase (PDE-5) inhibitor found in an FDA approved product for the treatment of male erectile dysfunction. The presence of sildenafil in Pink Pussycat capsules renders the product an unapproved drug for which the safety and efficacy has not been established and, therefore, subject to recall.

Risk Statement: Consumers with underlying medical conditions who take Pink Pussycat with undeclared sildenafil may experience serious health risks. For example, PDE-5 inhibitors may interact with nitrates found in some prescription drugs (such as nitroglycerin) lowering blood pressure to dangerous levels that may be life-threatening. Consumers with diabetes, high blood pressure, or heart disease often take nitrates. To date, 03/30/2022, Pink Toyz has not received any reports of adverse events related to this recall.

The product is marketed as a dietary supplement for male sexual enhancement and is packaged in 1 count blister pack, UPC [8 91875 00462 6]. The affected Pink Pussycat lot includes the following LOT# 2009066 and expiration date 09/2023 which was sold only by Pink Toyz The product can be identified by Pink Pussycat Sensual Enhancement capsule. Pink Pussycat was distributed nationwide to Walmart marketplaces.

Pink Toyz is notifying its distributors and customers by email and is arranging for return or destroy of all recalled product.

Consumers that have Pink Pussycat capsules which is being recalled should discard and ask for full refund where they placed order.

Consumers with questions regarding this recall can contact Pink Toyz at 747-202-3335 or [email protected] on Monday to Friday starting from 04/01/2022, 9 AM to 5 PM PST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact:
Sina Faghani
747-202-3335

Media Contact

Sina Faghani, F & S Medical Supply Inc, 1 7472023335, [email protected]

 

SOURCE F & S Medical Supply Inc


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: